Last reviewed · How we verify
NCT07403071
Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
trial testing Fish Oil (Containing Omega-3 Acids) in Multiple Myeloma in 200 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 May 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Fish Oil (Containing Omega-3 Acids) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Peripheral Neuropathy Due to Chemotherapy — all drugs for Peripheral Neuropathy Due to Chemotherapy →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
18 and older, any sex, with Multiple Myeloma or Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to find out if taking fish oil by mouth can help prevent or lessen a side effect called peripheral neuropathy in patients who are being treated with the chemotherapy drug bortezomib. We are mainly looking to answer one question: Can fish oil reduce the chances of getting this nerve damage, or make it less severe, for these patients?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07403071
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fish Oil (Containing Omega-3 Acids)
Trials testing the same drug.
- NCT04417595 — Omega-3 Fatty Acids for Smoking Cessation in Pregnancy · Phase 2 · active not recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
- NCT07372612 — Flow-diverting Devices for the Treatment of Middle Cerebral Artery Bifurcation Aneurysms · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07403071 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07403071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing